New cancer drug enters first human safety testing
NCT ID NCT04047251
Summary
This early-stage study aims to determine the safety and appropriate dosage of a new experimental cancer drug called FF-10850. The trial will enroll approximately 96 adults with advanced solid tumors that have not responded to standard treatments, including ovarian cancer and Merkel cell carcinoma. Researchers will give patients increasing doses of the drug to find the highest safe amount that can be tolerated while monitoring for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute (DFCI)
Boston, Massachusetts, 02215, United States
-
HonorHealth
Scottsdale, Arizona, 85258, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Ohio State University Wexner Medical Center
Columbus, Ohio, 43221, United States
-
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, 80218, United States
-
University of Wisconsin Clinical Science Center
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.